The thought on everyone's mind when looking at Amarin (NAS: AMRN) as an investor right now is: What approach is the company going to take in commercializing its new hypertriglyceridemia drug, Vascepa? Many people consider the company a potential acquisition target; others thought it would seek a partnership before going forward. But after the release of yesterday's conference call, the evidence might suggest that it plans to commercialize Vascepa on its own, an option that previously had some investors a little apprehensive. Motley Fool health care analyst Max Macaluso talks in this video about his take on Amarin's strategy going forward and why the CEO's words were well-received by the market.
The biotech space can make or break investors overnight, and while Amarin might not disappear into thin air, the success of Vascepa is key to the company's future success or failure, so the decisions the company makes in the coming months are going to be crucial. The company has huge potential, but don't invest a dollar before reading everything you need to know about Amarin. You can start now with top Fool.com analyst Max Macaluso's premium research report. Click here now to keep reading.
The article Could Amarin Reject a Buyout? originally appeared on Fool.com.Brenton Flynn has no positions in the stocks mentioned above. Max Macaluso, Ph.D. has no positions in the stocks mentioned above. The Motley Fool has no positions in the stocks mentioned above. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2012 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.